[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM#pubInfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/MONDO_0008114",
    "@type" : [ "https://w3id.org/biolink/vocab/Disease" ]
  }, {
    "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/MONDO_0008114"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/DRUGBANK:DB01175"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62]."
    } ],
    "https://w3id.org/biolink/vocab/has_population_context" : [ {
      "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM#context"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/publications" : [ {
      "@id" : "https://pubmed.ncbi.nlm.nih.gov/30101713"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://w3id.org/um/neurodkg/OffLabelIndication"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM#context",
    "@type" : [ "https://w3id.org/biolink/vocab/Cohort" ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "adults"
    } ]
  }, {
    "@id" : "https://identifiers.org/DRUGBANK:DB01175",
    "@type" : [ "https://w3id.org/biolink/vocab/Drug" ]
  } ],
  "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM#assertion",
    "http://www.w3.org/ns/prov#generatedAtTime" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-08-25T14:52:33.344024"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM",
    "http://www.w3.org/ns/prov#generatedAtTime" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-08-25T14:52:33.344024"
    } ],
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-7641-6446"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "ZhTHDwytjnomCNC0hmlbG+CJfBrD7z/xB70O6L0Rn+y7MK9gjicCRkdI3xpYiud7kWlvm4UHyvpn9dsgkarP/7Y0fC23KOQw5gPsRvvruPEeKojbMtMJfRvst7jbe4FTmoO+U002ZFOkNkL0odAoFPcMAhTnGvoIyOThakDUbow="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM#pubInfo"
} ]